A Phase 1b Study of Olaratumab, Doxorubicin and Ifosfamide in the Treatment of Patients With Advanced or Metastatic Soft Tissue Sarcoma

Trial Profile

A Phase 1b Study of Olaratumab, Doxorubicin and Ifosfamide in the Treatment of Patients With Advanced or Metastatic Soft Tissue Sarcoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 May 2018

At a glance

  • Drugs Doxorubicin (Primary) ; Ifosfamide (Primary) ; Olaratumab (Primary) ; Mesna
  • Indications Soft tissue sarcoma
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 10 May 2018 Planned End Date changed from 5 Aug 2019 to 1 Nov 2019.
    • 10 May 2018 Planned primary completion date changed from 5 Aug 2019 to 1 Nov 2019.
    • 18 Oct 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top